Divi’s Labs won big in a low-value segment with a curated portfolio. Will its dream run sustain?
✖
Dr. Murali K. Divi, managing director, Divi’s Laboratories Ltd.; Image courtesy: divislabs.com
Synopsis
The strong performance of Murali Divi’s company is a result of choosing the right products, securing scale, forging global partnerships, and keeping an unwavering eye on costs. Besides, in an industry with stringent quality standards, it has a clean report card. But will it be able to keep the ball rolling?
Drug maker Divi’s Laboratories has come to acquire a distinct edge that its peers envy. It has won the trust of customers and guarded itself relatively better against headwinds. Investors continue to believe in Divi’s, a deep bond they have shared since its listing in 2003. For months now, Divi’s has been sitting firmly atop the market capitalisation in its industry group, second only to Sun Pharmaceutical Industries. On July 20, Divi’s market
Get Unlimited Access to The Economic Times
